BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny(Beth Israel Deaconess Medical Center), Valerya Semenisty(Rambam Health Care Campus), Teresa Macarulla(Hebron University), Erkut Borazanci(Translational Genomics Research Institute), Brian M. Wolpin(Harvard University), Salomon M. Stemmer(Tel Aviv University), Talia Golan(Tel Aviv University), Ravit Geva(Tel Aviv University), Mitesh J. Borad(Mayo Clinic in Arizona), Katrina S. Pedersen(Washington University in St. Louis), Joon Oh Park(Samsung Medical Center), Robert A. Ramirez(Ochsner Medical Center), David Gutiérrez Abad(Hospital Universitario de Fuenlabrada), Jaime Feliú(Hospital Universitario La Paz), Andrés Muñoz(Hospital General Universitario Gregorio Marañón), Mariano Ponz‐Sarvisé(Clinica Universidad de Navarra), Amnon Peled(Hebrew University of Jerusalem), Tzipora M Lustig, Osnat Bohana‐Kashtan, Stephen M. Shaw, Ella Sorani, Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shaul Kadosh, Abi Vainstein Haras, Daniel D. Von Hoff(Translational Genomics Research Institute), Manuel Hidalgo(NewYork–Presbyterian Hospital)
Cited by 527
Abstract
Related Papers
No related papers found
Powered by citation graph analysis